The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Safety and efficacy of neoadjuvant combination of hepatic artery infusion (HAI) of irinotecan, 5-fluorouracil, and oxaliplatin with intravenous (iv) cetuximab in patients with unresectable liver metastases from colorectal cancer (CRC): Interim report from OPTILIV—A European multicenter phase II trial.
M. Ducreux
No relevant relationships to disclose
P. Rougier
No relevant relationships to disclose
D. Smith
No relevant relationships to disclose
C. N. J. Focan
No relevant relationships to disclose
P. F. Innominato
No relevant relationships to disclose
M. Bouchahda
No relevant relationships to disclose
Y. Ajavon
No relevant relationships to disclose
D. Castaing
No relevant relationships to disclose
T. De Baere
No relevant relationships to disclose
A. Karaboué
No relevant relationships to disclose
C. Lepere
No relevant relationships to disclose
V. Boige
No relevant relationships to disclose
R. Adam
No relevant relationships to disclose
F. Levi
No relevant relationships to disclose